Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andra antineoplastiska medel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiska medel - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacciner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

elanco animal health a/s/eli lilly danmark a/s - kattcalicivirus, stam f9, levande försvagat; kattpestvirus, stam snow leopard, levande försvagat; kattsnuvevirus, stam fvrm, levande försvagat - pulver och vätska till injektionsvätska, suspension - kattsnuvevirus, stam fvrm, levande försvagat 5 log10 ccid50 aktiv substans; laktos (vattenfri) hjälpämne; kattpestvirus, stam snow leopard, levande försvagat 3 log10 ccid50 aktiv substans; kattcalicivirus, stam f9, levande försvagat 5,5 log10 ccid50 aktiv substans - felint panleukopenivirus/parvovirus + felint rhinotrakeitvirus (kattsnuva) + felint calicivirus - katt

Europeiska unionen - svenska - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - autolog cd34+ cell berikad befolkningen som innehåller hematopoetiska stamceller transduced med lentiglobin bb305 lentiviral vektor kodning beta-en-t87q-globingenen - beta-talassemi - other hematological agents - zynteglo är indicerat för behandling av patienter som är 12 år och äldre med transfusion är beroende av β-thalassemi (tdt) som inte har en β0/β0 genotyp, för vem hematopoietiska stamceller (hsc) transplantation är lämpliga, men en human leukocyte antigen (hla-matchade relaterade hsc givare är inte tillgängligt.

Europeiska unionen - svenska - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcell - antineoplastiska medel - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Europeiska unionen - svenska - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - andra nervsystemet droger - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiska medel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - hypofysen och hypotalamus hormoner och derivat - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.